No price controls in Trump drug plan

President Donald Trump Friday announced a prescription drug pricing plan that seeks to increase pricing transparency, encourage Medicare to negotiate outcomes-based prices, and consider giving Medicare the ability to implement indication-based pricing. As expected, the plan does not include giving HHS power to negotiate Medicare Part D drug prices.

While Trump said his reforms “will bring soaring drug prices back down to earth,” the HHS plan does not commit the administration to taking steps that will have large effects on drug prices in the short

Read the full 859 word article

User Sign In